top
Search terms
Results 11 - 20 of 29 - ordered by :
Pages: 1 2 3
Heart

Background Renal impairment is associated with increased cardiovascular mortality following acute coronary syndromes (ACS), however there is limited data assessing this relationship in the context of ...

Heart, BCS Abstracts 2011, O P Guttmann, K Rathod, B Rathod, E Wicks, S Gallagher, D A Jones, A Jain, C Knight, A Mathur, A Kapur, A Wragg

Date : 01/06/2011
Eurointervention

[...]preprocedural measurements of CRP have been proposed to be a tool in identifying patients at higher risk of restenosis and recurrent events. Information was entered at the time of procedure and ...

Date : 17/05/2011 Item size : 34302 bytes
Ehjournal

[...]in-hospital mortality after acute PCI in ACS today is as low as <5%.24 The introduction of new anti-thrombotics and the increasing use of drug-eluting stents5 have the potential to improve the ...

European Heart Journal, Corti, Roberto, Toggweiler, Stefan

Date : 01/10/2009
Ehjournal

A higher rate of reperfusion in lytic-pre-treated patients did not result in lower NT-proBNP during follow-up. [...]baseline and subsequent NT-proBNP levels do not explain the lower mortality rate ...

European Heart Journal, Sinnaeve, Peter R., Ezekowitz, Justin A., Bogaerts, Kris, Droogne, Walter, Jarai, Rudolf, Huber, Kurt, Granger, Christopher B., Desmet, Walter J., Armstrong, Paul W., Van de ...

Date : 01/09/2009 Item size : 239987 bytes
Ehjournal

Abstract Aims Pexelizumab, a monoclonal antibody inhibiting C5, reduced 90 day mortality and shock in the COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA) trial without ...

European Heart Journal, Théroux, Pierre, Armstrong, Paul W., Mahaffey, Kenneth W., Hochman, Judith S., Malloy, Kevin J., Rollins, Scott, Nicolau, Jose C., Lavoie, Joel, Luong, The Minh, Burchenal, ...

Date : 01/10/2005
Ehjournal

Abstract Aims Pexelizumab, a monoclonal antibody inhibiting C5, reduced 90 day mortality and shock in the COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA) trial without ...

European Heart Journal, Théroux, Pierre, Armstrong, Paul W., Mahaffey, Kenneth W., Hochman, Judith S., Malloy, Kevin J., Rollins, Scott, Nicolau, Jose C., Lavoie, Joel, Luong, The Minh, Burchenal, ...

Date : 01/10/2005 Item size : 173396 bytes
Ehjournal

Abstract Aims Pexelizumab, a monoclonal antibody inhibiting C5, reduced 90 day mortality and shock in the COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA) trial without ...

European Heart Journal, Théroux, Pierre, Armstrong, Paul W., Mahaffey, Kenneth W., Hochman, Judith S., Malloy, Kevin J., Rollins, Scott, Nicolau, Jose C., Lavoie, Joel, Luong, The Minh, Burchenal, ...

Date : 01/10/2005
Ehjournal

Effect of thrombolytic therapy on the risk of cardiac rupture and mortality in older patients with first acute myocardial infarction Methods and results An analysis of 706 consecutive patients 75 ...

European Heart Journal, Bueno, Héctor, Martínez-Sellés, Manuel, Pérez-David, Esther, López-Palop, Ramón

Date : 01/09/2005
Ehjournal

Abstract Aims The CAPTIM study randomized patients managed within 6h of acute ST-segment elevation myocardial infarction to primary angioplasty or prehospital fibrinolysis (rt-PA), with immediate ...

European Heart Journal, Bonnefoy, Eric, Steg, Philippe Gabriel, Chabaud, Sylvie, Dubien, Pierre-Yves, Lapostolle, Frédéric, Boudet, Frédéric, Lacroute, Jean-Michel, Dissait, Frederic, ...

Date : 01/09/2005 Item size : 181232 bytes
Ehjournal

Abstract Aims To define the clinical characteristics, co-morbidities, treatment, and clinical outcomes of patients with varying degrees of heart failure (HF) complicating ST-elevation myocardial ...

European Heart Journal, Kashani, Amir, Giugliano, Robert P., Antman, Elliott M., Morrow, David A., Gibson, C. Michael, Murphy, Sabina A., Braunwald, Eugene

Date : 01/10/2004 Item size : 203819 bytes